Develops gedatolisib, a targeted cancer drug being tested for advanced breast cancer and metastatic prostate cancer.
10-K for FY2025, filed Mar 26, 2026We are a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor…View ↗
No revenue reported yet.
10-K for FY2021, filed Mar 23, 2022
10-Q for Q3 FY2026, filed Nov 5, 2026
−$73.3MView ↗
8-K, filed Aug 26, 2026
On August 26, 2026, Celcuity Inc. (the "Company") issued a press release announcing the submission of its supplemental New Drug Application…View ↗
8-K, filed Jul 15, 2026
On July 14, 2026, Celcuity Inc. (the “Company”) issued a press release announcing U.S. Food and Drug Administration (“FDA”) approval of…View ↗
Prostate cancer program
The earlier report described gedatolisib’s initial development program as focused on advanced breast cancer; the latest report also describes an ongoing study for metastatic prostate cancer.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 26, 2026Our therapeutic candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that…View ↗
We are a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor…View ↗
Loading...